Profile data is unavailable for this security.
About the company
CARGO Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in advancing curative cell therapies for cancer patients. Its programs, platform technologies, and manufacturing strategy are designed to directly address the chimeric antigen receptor (CAR) T-cell therapies. The CAR is a protein that has been engineered to modify T cells so they can recognize and destroy cancer cells. The Company’s lead program, firicabtagene autoleucel (CRG-022), is an autologous (derived from a patient’s cells) CD22 CAR T-cell product candidate. The Company is also engaged in evaluating CRG-022 in patients at earlier stages of disease, including large B-cell lymphoma (LBCL) and other hematologic malignancies. The Company is also leveraging its proprietary cell engineering platform technologies to develop a pipeline of programs that incorporate multiple transgene therapeutic designed by the Company to enhance CAR T-cell persistence and trafficking to tumor lesions.
- Revenue in USD (TTM)0.00
- Net income in USD-98.15m
- Incorporated2019
- Employees116.00
- LocationCARGO Therapeutics Inc1900 Alameda De Las Pulgas, Suite 350SAN MATEO 94403United StatesUSA
- Phone+1 (650) 379-6143
- Websitehttps://cargo-tx.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Phibro Animal Health Corp | 999.56m | 13.16m | 710.84m | 1.92k | 54.02 | 2.63 | 14.59 | 0.7112 | 0.3249 | 0.3249 | 24.68 | 6.67 | 1.03 | 2.42 | 6.37 | 520,606.30 | 1.35 | 5.46 | 1.66 | 6.83 | 30.33 | 31.41 | 1.32 | 5.11 | 1.67 | 2.26 | 0.6427 | 42.99 | 3.78 | 3.59 | -33.69 | -13.56 | 22.80 | 3.71 |
| Dianthus Therapeutics Inc | 3.22m | -50.21m | 712.88m | 53.00 | -- | 1.91 | -- | 221.12 | -3.20 | -3.20 | 0.2721 | 12.70 | 0.0138 | -- | -- | 60,830.19 | -21.56 | -41.40 | -22.27 | -44.70 | -- | -- | -1,557.51 | -12,132.27 | -- | -- | 0.00 | -- | -- | -- | 43.04 | -- | -57.21 | -- |
| SAGE Therapeutics Inc | 91.06m | -503.14m | 716.17m | 487.00 | -- | 1.01 | -- | 7.86 | -8.40 | -8.40 | 1.52 | 11.73 | 0.0916 | -- | 6.26 | 186,989.70 | -50.61 | -21.88 | -54.64 | -23.30 | 96.49 | 99.63 | -552.52 | -131.50 | -- | -- | 0.00 | -- | 1,024.84 | -0.8606 | -1.63 | -- | -28.01 | -- |
| Aurinia Pharmaceuticals Inc | 191.41m | -62.56m | 717.96m | 300.00 | -- | 2.01 | -- | 3.75 | -0.4363 | -0.4363 | 1.34 | 2.50 | 0.3953 | 0.6008 | 7.98 | 638,023.30 | -12.92 | -25.97 | -14.63 | -28.24 | 88.78 | -- | -32.69 | -137.64 | 5.05 | -- | 0.1843 | -- | 30.95 | 227.90 | 27.88 | -- | 57.11 | -- |
| Cogent Biosciences Inc | 0.00 | -212.17m | 722.84m | 164.00 | -- | 3.61 | -- | -- | -2.47 | -2.47 | 0.00 | 4.42 | 0.00 | -- | -- | 0.00 | -57.40 | -49.53 | -62.27 | -54.94 | -- | -- | -- | -1,684.44 | -- | -- | 0.00 | -- | -- | -- | -37.20 | -- | 38.48 | -- |
| SS Innovations International Inc | 5.88m | -20.94m | 725.58m | 239.00 | -- | 50.74 | -- | 123.40 | -0.1293 | -0.1293 | 0.04 | 0.0838 | 0.3939 | -- | 2.53 | 24,601.30 | -140.31 | -161.38 | -253.40 | -449.76 | 12.13 | -79.79 | -356.17 | -495.77 | 1.30 | -52.51 | 0.2963 | -- | -- | -- | -846.31 | -- | 159.31 | -- |
| Arcturus Therapeutics Holdings Inc | 124.53m | -107.30m | 734.06m | 180.00 | -- | 2.78 | -- | 5.89 | -4.02 | -4.02 | 4.66 | 9.81 | 0.2799 | -- | 2.08 | 691,811.10 | -24.12 | -19.66 | -31.37 | -24.90 | -- | -- | -86.16 | -77.55 | -- | -- | 0.00 | -- | -19.03 | 60.31 | -417.95 | -- | 14.44 | -- |
| National Research Corporation | 147.42m | 30.36m | 741.45m | 435.00 | 24.96 | -- | 20.41 | 5.03 | 1.24 | 1.24 | 6.02 | -- | 1.16 | -- | 11.56 | 338,896.60 | 23.80 | 26.25 | 35.67 | 36.77 | 62.29 | 63.20 | 20.60 | 23.95 | -- | 132.00 | 0.5325 | 55.45 | -1.97 | 4.42 | -2.58 | 0.6695 | 21.45 | -5.29 |
| Disc Medicine Inc | 0.00 | -80.60m | 750.54m | 74.00 | -- | 2.22 | -- | -- | -3.37 | -3.37 | 0.00 | 13.69 | 0.00 | -- | -- | 0.00 | -26.96 | -- | -28.13 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -63.22 | -- | -- | -- |
| CARGO Therapeutics Inc | 0.00 | -98.15m | 751.55m | 116.00 | -- | 1.94 | -- | -- | -2.37 | -2.37 | 0.00 | 9.84 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -139.67 | -- | -- | -- |
| Regenxbio Inc | 86.73m | -260.15m | 757.22m | 344.00 | -- | 1.94 | -- | 8.73 | -5.88 | -5.88 | 1.96 | 7.97 | 0.126 | -- | 5.00 | 252,110.50 | -37.78 | -16.75 | -45.07 | -19.08 | 56.89 | 78.27 | -299.97 | -72.06 | -- | -- | 0.00 | -- | -19.94 | -16.21 | 6.00 | -- | -5.59 | -- |
| Tango Therapeutics Inc | 37.23m | -111.65m | 758.36m | 140.00 | -- | 2.87 | -- | 20.37 | -1.11 | -1.11 | 0.3742 | 2.48 | 0.0919 | -- | -- | 265,942.80 | -27.57 | -- | -31.29 | -- | -- | -- | -299.88 | -- | -- | -- | 0.00 | -- | 46.93 | -- | 5.95 | -- | -- | -- |
| Longboard Pharmaceuticals Inc | 0.00 | -57.95m | 782.27m | 50.00 | -- | 2.49 | -- | -- | -2.25 | -2.25 | 0.00 | 8.07 | 0.00 | -- | -- | 0.00 | -28.45 | -- | -29.73 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -23.84 | -- | -- | -- |
| Evolus Inc | 219.70m | -60.00m | 798.28m | 279.00 | -- | 43.05 | -- | 3.63 | -1.05 | -1.05 | 3.82 | 0.2962 | 1.14 | 3.86 | 7.62 | 804,750.90 | -31.06 | -40.92 | -40.14 | -59.74 | 69.28 | 65.43 | -27.31 | -80.46 | 2.96 | -2.90 | 0.8674 | -- | 35.98 | -- | 17.10 | -- | 182.77 | -- |
| Nurix Therapeutics Inc | 80.89m | -144.73m | 801.19m | 284.00 | -- | 3.93 | -- | 9.91 | -2.65 | -2.65 | 1.48 | 3.43 | 0.2369 | -- | -- | 284,813.40 | -42.39 | -33.01 | -54.58 | -39.66 | -- | -- | -178.93 | -260.65 | -- | -- | 0.00 | -- | 99.31 | 15.50 | 20.19 | -- | 39.42 | -- |
Data as of May 10 2024. Currency figures normalised to CARGO Therapeutics Inc's reporting currency: US Dollar USD
63.82%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Fidelity Management & Research Co. LLCas of 31 Dec 2023 | 5.68m | 14.44% |
| RTW Investments LPas of 12 Jan 2024 | 5.18m | 13.15% |
| Perceptive Advisors LLCas of 31 Dec 2023 | 3.44m | 8.73% |
| Janus Henderson Investors US LLCas of 31 Dec 2023 | 2.70m | 6.86% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 2.22m | 5.64% |
| Wellington Management Co. LLPas of 31 Dec 2023 | 1.71m | 4.35% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 1.36m | 3.45% |
| Cormorant Asset Management LPas of 31 Dec 2023 | 1.18m | 3.00% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.08m | 2.73% |
| Franklin Advisers, Inc.as of 31 Dec 2023 | 575.92k | 1.46% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
